AG
LXRX icon

Advisor Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Advisor Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Sell
225
-82
-27% -$316 ﹤0.01% 5157
2019
Q3 		$0 Hold
307
– – ﹤0.01% 5355
2019
Q2 		$2K Sell
307
-15
-5% -$90 ﹤0.01% 4985
2019
Q1 		$2K Hold
322
– – ﹤0.01% 4959
2018
Q4 		$2K Sell
322
-172
-35% -$1.39K ﹤0.01% 4827
2018
Q3 		$6K Buy
494
+281
+132% +$3.22K ﹤0.01% 4515
2018
Q2 		$3K Hold
213
– – ﹤0.01% 4556
2018
Q1 		$1K Buy
213
+16
+8% +$148 ﹤0.01% 4824
2017
Q4 		$2K Sell
197
-488
-71% -$5.07K ﹤0.01% 4693
2017
Q3 		$8K Buy
685
+144
+27% +$2.13K ﹤0.01% 4084
2017
Q2 		$9K Sell
541
-267
-33% -$4.13K ﹤0.01% 3978
2017
Q1 		$11K Buy
808
+397
+97% +$5.89K ﹤0.01% 3728
2016
Q4 		$5K Sell
411
-281
-41% -$4.51K ﹤0.01% 3938
2016
Q3 		$12K Buy
692
+81
+13% +$1.3K ﹤0.01% 3450
2016
Q2 		$7K Buy
+611
New +$8.29K ﹤0.01% 3639

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Advisor Group's LXRX Position: Q4 2019 in Review

Advisor Group reduced its Lexicon Pharmaceuticals (LXRX) stake by 27% in Q4 2019, selling an estimated $316 and leaving 225 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5157.

Advisor Group first reported a position in LXRX in Q2 2016 and has held it in 15 quarters since. The position peaked at $12K in Q3 2016. 115 funds tracked by Wall St. Rank hold LXRX as of Q4 2019.

  • Advisor Group held 225 shares of Lexicon Pharmaceuticals worth $1K as of Q4 2019.
  • Advisor Group sold 82 Lexicon Pharmaceuticals shares in Q4 2019, an estimated $316.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5157 holding.
  • Advisor Group first reported a position in Lexicon Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Lexicon Pharmaceuticals position peaked at $12K in Q3 2016.
  • 115 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.